Johnson & Johnson (JNJ) Short-Term Debt issuances (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Short-Term Debt issuances came in at $12.4 billion in Q1 2026, up 41.61% year-on-year from $8.8 billion in Q1 2025, and up 217.89% quarter-over-quarter from $3.9 billion in Q4 2025.
Johnson & Johnson (JNJ) Short-Term Debt issuances (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Short-Term Debt issuances across 18 years of filings, most recently posting $12.4 billion for Q1 2026.
- Short-Term Debt issuances for Q1 2026 came in at $12.4 billion, up 41.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.2 billion (down 2.96% YoY), and the FY2025 annual result was $14.6 billion, down 4.52% from the prior year.
- Short-Term Debt issuances came in at $12.4 billion for Q1 2026 at Johnson & Johnson, up from $3.9 billion in the prior quarter.
- In the past five years, Short-Term Debt issuances ranged from a high of $14.9 billion in Q1 2023 to a low of -$2.0 billion in Q3 2024.
- The 5-year median for Short-Term Debt issuances is $3.3 billion (2024), against an average of $4.9 billion.
- Across the five-year window, Short-Term Debt issuances surged 13026.09% in 2022 and sank 926.56% in 2024, its largest moves.
- Johnson & Johnson's Short-Term Debt issuances stood at $3.0 billion in 2022, then sank by 57.57% to $1.3 billion in 2023, then surged by 157.06% to $3.3 billion in 2024, then gained by 18.83% to $3.9 billion in 2025, then soared by 217.89% to $12.4 billion in 2026.
- The last three Short-Term Debt issuances figures came in at $12.4 billion (Q1 2026), $3.9 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ST Debt Issuance (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | 1.61 Bn |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | 1.78 Bn |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | 12.44 Bn |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | -499.00 Mn |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | 1.06 Bn |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | -127.00 Mn |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | 321.00 Mn |
| 10 | Novartis Ag | 108.02 Bn | 107.33 Bn | - | 747.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 12.44 Bn |
| Mar 29, 2026 | 12.44 Bn |
| Dec 28, 2025 | 3.91 Bn |
| Dec 28, 2025 | 3.91 Bn |
| Sep 28, 2025 | 1.32 Bn |
| Sep 28, 2025 | 1.32 Bn |
| Jun 29, 2025 | 565.00 Mn |
| Jun 29, 2025 | 565.00 Mn |
| Mar 30, 2025 | 8.78 Bn |
| Mar 30, 2025 | 8.78 Bn |
| Dec 29, 2024 | 3.29 Bn |
| Dec 29, 2024 | 3.29 Bn |
| Sep 29, 2024 | -1.99 Bn |
| Sep 29, 2024 | -1.99 Bn |
| Jun 30, 2024 | 8.71 Bn |
| Jun 30, 2024 | 8.71 Bn |
| Mar 31, 2024 | 5.26 Bn |
| Mar 31, 2024 | 5.26 Bn |
| Dec 31, 2023 | 1.28 Bn |
| Dec 31, 2023 | 1.28 Bn |